{"prompt": "['Novartis', 'Confidential', 'Page 54', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '7 Safety monitoring', '7.1 Adverse events', 'An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and', 'unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or', 'clinical investigation subject after providing written informed consent for participation in the', 'study until the end of study visit. Therefore, an AE may or may not be temporally or causally', 'associated with the use of a medicinal (investigational) product.', 'In addition, all reports of intentional misuse and abuse of the product are also considered an', 'adverse event irrespective if a clinical event has occurred.', 'The occurrence of adverse events must be sought by non-directive questioning of the patient', 'at each visit during the study. Adverse events also may be detected when they are volunteered', 'by the patient during or between visits or through physical examination findings, laboratory', 'test findings, or other assessments.', 'Abnormal laboratory values or test results constitute adverse events only if they fulfill at least', 'one of the following criteria:', 'they induce clinical signs or symptoms,']['Novartis', 'Confidential', 'Page 55', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'they are considered clinically significant,', 'they require therapy.', 'Clinically significant abnormal laboratory values or test results must be identified through a', 'review of values outside of normal ranges/clinically notable ranges, significant changes from', 'baseline or the previous visit, or values which are considered to be non-typical in patient with', 'underlying disease. Investigators have the responsibility for managing the safety of individual', 'patient and identifying adverse events. Alert ranges for laboratory and other test abnormalities', 'are included in Appendix 1.', 'Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or', 'diagnosis associated with them, accompanied by the following information:', 'the severity grade', 'mild: usually transient in nature and generally not interfering with normal activities', 'moderate: sufficiently discomforting to interfere with normal activities', 'severe: prevents normal activities', 'All adverse events must be treated appropriately. Treatment may include one or more of the', 'following:', 'no action taken (e.g. further observation only)', '[investigational] treatment dosage adjusted/temporarily interrupted', '[investigational] treatment permanently discontinued due to this adverse event', 'concomitant medication given', 'non-drug therapy given', \"patient hospitalized/patient's hospitalization prolonged (see Section 7.2) for definition of\", 'SAE)', 'its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving,', 'recovered/resolved with sequelae; fatal; or unknown)', 'Once an adverse event is detected, it must be followed until its resolution or until it is judged', 'to be permanent, and assessment must be made at each visit (or more frequently, if necessary)', 'of any changes in severity, the suspected relationship to the study drug, the interventions', 'required to treat it, and the outcome.', 'Information about common side effects already known about the investigational drug can be', 'found in the Investigator Brochure (IB). This information will be included in the patient', 'informed consent and should be discussed with the patient during the study as needed. Any', 'new information regarding the safety profile of the medicinal product that is identified', 'between IB updates will be communicated as appropriate, for example, via an Investigator', 'Notification or an Aggregate Safety Finding. New information might require an update to the', 'informed consent and has then to be discussed with the patient.', 'The investigator must also instruct each patient to report any new adverse event (beyond the', \"protocol observation period) that the patient, or the patient's personal physician, believes\", 'might reasonably be related to study treatment. This information must be recorded in the']['Novartis', 'Confidential', 'Page 56', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', \"investigator's source documents; however, if the AE meets the criteria of an SAE, it must be\", 'reported to Novartis.', '7.2 Serious adverse events', '7.2.1 Definition of SAE', 'A SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)]', 'undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the', 'following criteria:', 'is fatal or life-threatening', 'results in persistent or significant disability/incapacity', 'constitutes a congenital anomaly/birth defect', 'requires inpatient hospitalization or prolongation of existing hospitalization, unless', 'hospitalization is for:', 'routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition (specify what this includes)', 'elective or pre-planned treatment for a pre-existing condition that is unrelated to the', 'indication under study and has not worsened since signing the informed consent', 'treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of a SAE given above and not resulting in hospital admission', \"social reasons and respite care in the absence of any deterioration in the patient's\", 'general condition', 'is medically significant, e.g. defined as an event that jeopardizes the patient or may', 'require medical or surgical intervention.', 'All malignant neoplasms will be assessed as serious under \"medically significant\" if other', 'seriousness criteria are not met.', 'Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of', 'death at the time of the reaction; it does not refer to a reaction that hypothetically might have', 'caused death if it were more severe (see Annex IV, ICH-E2D Guideline).', 'Medical and scientific judgment should be exercised in deciding whether other situations', 'should be considered serious reactions, such as important medical events that might not be', 'immediately life threatening or result in death or hospitalization but might jeopardize the', 'patient or might require intervention to prevent one of the other outcomes listed above.', 'Examples of such events are intensive treatment in an emergency room or at home for allergic', 'bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or', 'development of dependency or abuse (see Annex IV, ICH-E2D Guideline).', 'Any suspected transmission via a medicinal product of an infectious agent is also considered a', 'serious adverse reaction.']\n\n###\n\n", "completion": "END"}